Quantcast

Latest Amgen Stories

2014-06-18 12:39:39

SUNNYVALE, Calif., June 18, 2014 /PRNewswire/ -- Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today announced the appointment of Jay Shepard and William D. Waddill to the company's Board of Directors. Mr. Shepard currently serves as an Executive Partner at Sofinnova Ventures and has more than 32 years of commercial and company building experience in the specialty pharmaceutical and biotechnology industry. Mr....

2014-06-16 16:25:14

Lung-MAP Trial Will Test Five Investigational Approaches, Including Amgen's Rilotumumab, an Investigational Fully Human Monoclonal Antibody THOUSAND OAKS, Calif., June 16, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that it will collaborate with the National Cancer Institute (NCI), part of the National Institutes of Health, and other public and private sector partners on the Lung Master Protocol (Lung-MAP), a groundbreaking new clinical trial program that will use...

2014-06-16 08:29:32

The Lung-MAP trial uses a multi-drug, targeted screening approach to match patients with promising new cancer treatments based on their unique tumor profiles BETHESDA, Md., June 16, 2014 /PRNewswire/ -- A unique public-private collaboration among the National Cancer Institute (NCI), part of the National Institutes of Health, SWOG Cancer Research, Friends of Cancer Research (Friends), the Foundation for the National Institutes of Health (FNIH), five pharmaceutical companies (Amgen,...

2014-06-11 16:27:22

Phase 3 Program Underway to Further Assess Brodalumab as Potential Treatment for People Living With Psoriatic Arthritis THOUSAND OAKS, Calif. and LONDON, June 11, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that results from a Phase 2 study evaluating brodalumab in 168 patients with psoriatic arthritis were published in The New England Journal of Medicine (NEJM). These data will also be presented at the 2014 European League Against Rheumatism (EULAR)...

2014-06-10 16:26:06

SANTA MONICA, Calif., June 10, 2014 /PRNewswire/ -- Kite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced the expansion of Kite's research and development leadership team with the appointments of William Y. Go, M.D., Ph.D., as Senior Director, Clinical Development and Jeff Aycock as Senior Director, Clinical Operations....

2014-06-09 16:25:38

THOUSAND OAKS, Calif., June 9, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the appointment of David W. Meline as executive vice president and chief financial officer (CFO), effective July 21, 2014. He will be responsible for Amgen's finance and investor relations operations, reporting to Robert A. Bradway, chairman and chief executive officer. Meline will succeed Michael A. Kelly, who served as acting CFO since January 2014. Meline, 56, joins Amgen from 3M Company, where...

2014-06-06 16:23:57

THOUSAND OAKS, Calif., June 6, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs Global Healthcare Conference at 1:20 p.m. PT on Wednesday, June 11, 2014, at the Terranea Resort in Rancho Palos Verdes, Calif. Anthony C. Hooper, executive vice president of Global Commercial Operations at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of...

2014-06-02 08:30:06

New Chief Medical Officer Brings Wealth of Experience in Innovative Therapies in Oncology SANTA MONICA, Calif., June 2, 2014 /PRNewswire/ -- Kite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced the appointment of David D. Chang, M.D., Ph.D., as Executive Vice President, Research and Development, and Chief Medical Officer. Dr. Chang brings a substantial...

2014-06-02 08:29:32

Phase 1 Study Evaluating Talimogene Laherparepvec Plus Ipilimumab Showed Tolerability at Doses Administered THOUSAND OAKS, Calif., June 2, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from two key clinical trials that support the potential of talimogene laherparepvec, a novel, investigational oncolytic immunotherapy, as both a single agent and as part of a combination regimen in patients with metastatic melanoma. The findings were presented at the 50th...

2014-06-01 12:20:22

Data From Phase 3 TESLA Study in Patients With Homozygous Familial Hypercholesterolemia (HoFH) and Phase 2/3 TAUSSIG Study in Patients With Severe Familial Hypercholesterolemia Presented in Late-Breaking Session at EAS 2014 THOUSAND OAKS, Calif., June 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new detailed data from the Phase 3 TESLA study evaluating its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), in patients with homozygous...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related